Niagen Bioscience (NAGE): Customer Relationships and Commercial Footprint

Niagen Bioscience commercializes pharmaceutical‑grade nicotinamide riboside (Niagen) through a dual revenue model: ingredient sales to strategic partners and B2B channels plus direct consumer sales via TruNiagen and major marketplaces. The business monetizes by supplying high‑margin Niagen to brand and clinical partners while expanding clinical and medi‑spa channels for IV and injectable products, driving both recurring ingredient contracts and direct-to-consumer margin expansion. For deeper coverage of counterparty signals and relationship mapping, visit https://nullexposure.com/.

What investors need to know about the operating model and commercial constraints

Niagen’s disclosures and public reporting reveal a predictable commercial posture: concentrated, commercialized manufacturing with material customer exposures and an expanding clinical channel. Key company‑level signals derived from filings and press material:

• Concentration and materiality: The 2024 10‑K states two customers accounted for more than 10% of net sales in 2024, signaling top‑customer concentration risk that can drive near‑term revenue volatility. (10‑K, FY2024)
• Direct-to‑consumer distribution: The company distributes Tru Niagen through its proprietary e‑commerce site and major marketplaces such as Amazon and ShopHQ, indicating dual channel economics and consumer funnel control. (Company disclosure excerpt)
• Manufacturer posture: Niagen supplies pharmaceutical‑grade product to FDA‑registered 503B outsourcing facilities for IV and injectable applications, underscoring the company’s manufacturing role and regulatory sensitivity in clinical/med‑spa channels. (Company disclosure excerpt)
• Geography: Domestic U.S. distribution is core, but international partners such as A.S. Watson generate meaningful revenue; 24% of revenue in 2024 came from international sales per a press statement. (Press release, FY2025)
• Research validation channel: A growing research program with leading institutions supplies clinical credibility and supports demand in clinical and medi‑spa settings. (Press releases, FY2026)

For a compact market map and counterparty scoring, see the firm’s relationship model at https://nullexposure.com/.

Customer relationships: each named counterparty and what they mean for NAGE

A.S. Watson Group

A.S. Watson Group accounted for ~12.5% of Niagen’s net sales in FY2024 (and ~15.4% in FY2023), making it a material retail partner that drives international B2B distribution. — 10‑K (FY2024).

Watson’s (Hong Kong)

Watson’s supported B2B distribution revenue with notable weight in Hong Kong; management cited Watson’s as a key driver of a $7.3M quarter in B2B distribution. — Earnings transcript / Globe and Mail (FY2026).

Life Extension

Life Extension represented ~11.7% of net sales for the year ended December 31, 2024, marking it as one of two major customers contributing material revenue concentration. — 10‑K (FY2024).

Elysium Health, Inc.

Elysium Health was a party to litigation resolved by a binding settlement agreement referenced in Niagen’s filing, indicating a concluded legal relationship that has been settled. — 10‑K (FY2024).

NHSc

NHSc and its affiliates are committed to exclusive purchase arrangements for nicotinamide riboside chloride (NRCL) from Niagen, reflecting an exclusivity commercial outlet for a specific product form. — 10‑K (FY2024).

Mayo Clinic

Niagen’s research program lists Mayo Clinic as a requesting institution for clinical and preclinical Niagen studies, reinforcing institutional validation and research‑led demand. — Biospace press release (Mar 2026).

Harvard University

Harvard University is among the top academic investigators requesting Niagen for clinical/preclinical work, supporting third‑party scientific validation. — Biospace / PharmiWeb press releases (Mar 2026).

Cambridge University

Cambridge University likewise participates in Niagen research agreements, contributing to the company’s growing portfolio of academic collaborations. — Biospace / PharmiWeb press releases (Mar 2026).

National Institutes of Health (NIH)

The NIH is cited among institutions requesting Niagen for research, providing a high‑credibility endorsement that supports clinical adoption. — Biospace / PharmiWeb press releases (Mar 2026).

NSRGY (Nestlé reference)

Industry commentary references Nestlé (ticker NSRGY) as a partner example in Niagen’s ingredient supply channel, highlighting blue‑chip co‑sourcing opportunities for ingredient partnerships. — Finviz commentary (FY2026).

Nestlé

Nestlé is specifically cited in market analysis as an example of strategic ingredient partnerships, underscoring the scalability of enterprise supply agreements. — Finviz analysis (FY2026).

Thorne

Thorne is named as a partner in the ingredient supply channel, illustrating Niagen’s go‑to‑market with established supplement brands. — Finviz analysis (FY2026).

iCRYO / iCRYO centers

Niagen Plus products, including Niagen IV, are deployed across over 50 iCRYO centers within a U.S. network of 900+ wellness clinics, signaling rapid clinical channel expansion. — RTTNews / Investing (FY2025/FY2026).

Hydra Heal

Hydra Heal is listed among new clinic providers offering Niagen IV, reflecting expansion into individual clinic partnerships. — Yahoo Finance press release (FY2025).

Arete

Arete (Nashville, TN) is named as a new clinical provider for pharmaceutical‑grade Niagen IV. — Yahoo Finance press release (FY2025).

Beautologie

Beautologie (Bakersfield, CA) is included in the clinic roll‑out, showing geographic breadth in clinic adoption. — Yahoo Finance press release (FY2025).

Beyond Remedi

Beyond Remedi (Saint Paul, MN) is a newly reported clinic partner carrying Niagen Plus treatments. — Yahoo Finance press release (FY2025).

Clarus Health

Clarus Health (San Francisco, CA) was cited among clinics commencing Niagen IV services. — Yahoo Finance press release (FY2025).

Energy4Life Centers

Energy4Life Centers (Park City, UT) is a named clinic partner offering Niagen IV, contributing to the med‑spa distribution footprint. — Yahoo Finance press release (FY2025).

Kahala Clinic

Kahala Clinic (Honolulu, HI) is part of the expansion of Niagen IV clinic providers. — Yahoo Finance press release (FY2025).

LifeMed Institute

LifeMed Institute (multiple U.S. locations) appears in Niagen’s clinic roll‑out list, demonstrating multi‑site clinic partnerships. — Yahoo Finance press release (FY2025).

Longevity LA

Longevity LA (Los Angeles) is listed among clinics introducing Niagen IV, important for local market penetration near corporate HQ. — Yahoo Finance press release (FY2025).

Navo

Navo (New York, NY) is a named provider adding Niagen IV services in a major urban market. — Yahoo Finance press release (FY2025).

PEAQ Society

PEAQ Society (Kansas City, MO) is a listed clinic partner expanding regional medi‑spa adoption. — Yahoo Finance press release (FY2025).

OneSpaWorld / OSW

OneSpaWorld (OSW) has been engaged to offer pharmaceutical‑grade Niagen IV at over 80 medi‑spa clinics onboard high‑end cruise ships, marking entry into travel and cruise wellness markets. — Company press releases and market coverage (May 2026).

Amazon / AMZN

Niagen distributes directly to consumers through its e‑commerce channel and across major marketplaces like Amazon, supporting scale in DTC and third‑party digital reach. — Directorstalkinterviews and company statements (FY2026).

LGC / LGCB

Niagen announced the sale of its ChromaDex reference standards business to LGC (LGCB) in an all‑cash transaction as part of operational streamlining, signaling a narrower focus on core Niagen manufacturing and commercial channels. — Reuters / TradingView / Finviz coverage (FY2026).

Investment implications and risk framing

• Revenue concentration is a primary risk given two customers accounted for >10% of sales in 2024; A.S. Watson and Life Extension represent significant single‑counterparty exposures. (10‑K, FY2024)
• Margin and channel upside derives from the dual model: ingredient contracts with enterprise partners and higher‑margin DTC and clinical services (IV/injectable), supported by institutional research demand that strengthens product credibility. (Company disclosures, press releases FY2025–FY2026)
• Regulatory and partner execution sensitivity is embedded in the manufacturer role to 503B facilities and the sale/streamlining of non‑core reference standards, both of which concentrate management focus on commercial Niagen growth. (10‑K; Reuters, FY2026)

For practitioner‑grade relationship mapping and to monitor material counterparties continuously, see our research hub at https://nullexposure.com/.